BREAST 1. Risk Factors for breast cancer, including familial breast cancers 2. Pathological types, Molecular subtypes and metastasis 3. Clinical hallmarks 4. Staging, investigations 5. BCT and other treatment modalities 6. Management of breast abscess 7. DCIS vS LCIS vs Pagets 8. Phylloides tumor-presentation, pathology and Neet pg previous years questions High yield questions and alao generate colored mindmap of topic breast including all important things

Reading File

Finding Sources

Searching the Web

NEET PG previous year questions breast cancer surgery MCQ high yield

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching the Web

NEET PG breast cancer MCQ phyllodes tumor Paget disease breast abscess surgery questions answers

Generating Image

Here is the complete, NEET PG-focused revision of Breast Surgery - covering all 8 topics with high-yield points, previous year question patterns, and the mindmap.

🩺 BREAST CANCER - Complete NEET PG Revision

🗺️ COLORED MINDMAP

1. RISK FACTORS FOR BREAST CANCER

Sources: Sabiston Textbook of Surgery, Bailey & Love's Surgery 28e

NON-MODIFIABLE Risk Factors

Factor	Details
Age	Most important risk factor; rare <20 yrs; median age ~60 yrs West, ~48 yrs India
Female sex	Only 0.5-1% of breast cancers in males
Family history	1 first-degree relative: RR = 2; 2 first-degree relatives: RR = 3
BRCA mutations	Hereditary breast cancer = 5-10% of all cases
Early menarche	<12 years; risk increases ~5% per year earlier
Late menopause	>55 years; risk increases ~3% per year later
Ethnicity	Ashkenazi Jews, Parsi in India, American white

MODIFIABLE Risk Factors

Factor	Details
Obesity	BMI >30; RR = 1.29 (postmenopausal)
Nulliparity / late first pregnancy	First full-term pregnancy after 35: high risk
No breastfeeding	>12 months breastfeeding is protective
HRT use	>10 years; RR = 1.2
Alcohol	Heavy drinking >4 drinks/day: RR = 1.46
Radiation exposure	Especially chest radiation <30 yrs; RR = 6
Shift work (nighttime)	Disrupts circadian rhythm / melatonin

FAMILIAL / HEREDITARY BREAST CANCER

Sporadic: 65-75% of all breast cancers
Familial (without known mutation): 20-30%
Hereditary (identified mutation): 5-10%

BRCA1 - chromosome 17q21 - causes 45% of hereditary breast cancers

Lifetime breast cancer risk: 65-85%
Associated: ovarian cancer, triple-negative breast cancer

BRCA2 - chromosome 13q12 - causes 35% of hereditary breast cancers

Associated: male breast cancer, pancreatic cancer, prostate cancer

Mnemonic for other hereditary syndromes - "PLACH":

P - Peutz-Jeghers (STK11/LKB1)
L - Li-Fraumeni (p53 mutation)
A - Ataxia-telangiectasia (ATM)
C - Cowden disease (PTEN)
H - HNPCC/Muir-Torre (MLH1/MSH2)

Histologic risk factors (relative risk):

Proliferative disease without atypia: RR 1.3-1.9

Atypical ductal/lobular hyperplasia (ADH/ALH): RR 3.7-4.2

LCIS: RR >7 (highest)

2. PATHOLOGICAL TYPES, MOLECULAR SUBTYPES & METASTASIS

WHO Classification of Breast Carcinoma

IN SITU:

DCIS (Ductal Carcinoma in Situ)
LCIS (Lobular Carcinoma in Situ)

INVASIVE CARCINOMA:

Type	Frequency	Key Features
Invasive Ductal Carcinoma (IDC/NST)	80% - MC	Hard, stellate, fibrous stroma; "rock hard" mass
Invasive Lobular Carcinoma	10-15%	Single-file "Indian file" pattern; multicentric, bilateral tendency
Tubular Carcinoma	Rare	Excellent prognosis; single layer cells lining tubules
Mucinous/Colloid	Rare	Tumor cells float in lakes of mucin; good prognosis
Medullary Carcinoma	Rare	Large undifferentiated cells + lymphocytic infiltrate + syncytial sheets; associated with BRCA1
Papillary Carcinoma	Rare	Usually ER+, good prognosis
Inflammatory Carcinoma	1-3%	Worst prognosis; dermal lymphatic invasion; peau d'orange; NOT a histological diagnosis - clinical diagnosis
Paget's Disease	<1%	Nipple involvement; intraepidermal adenocarcinoma

Molecular Subtypes (PAM50 Classification)

Subtype	Receptor Status	Ki-67	Prognosis	Treatment
Luminal A	ER+, PR+, HER2-	Low (<14%)	Best	Hormonal therapy
Luminal B	ER+, PR+/-, HER2+ OR HER2- with high Ki-67	High	Intermediate	Hormonal + Chemo
HER2-enriched	ER-, PR-, HER2+	High	Poor	Trastuzumab + Chemo
Triple Negative / Basal-like	ER-, PR-, HER2-	High	Worst	Chemo only (no targeted therapy); associated with BRCA1

Lymphatic Metastasis

Primary route: Axillary lymph nodes (75%) - via lateral group
Internal mammary nodes (medial/central lesions)
Supraclavicular nodes (N3 disease)
Lymphatic spread via the subareolar plexus of Sappey

Haematogenous Metastasis

Bone (most common site, especially lumbar spine, pelvis)
Lung
Liver
Brain
Adrenals

3. CLINICAL HALLMARKS

Symptoms:

Hard, painless lump (MC presenting feature) - "rock hard" consistency
Skin dimpling / tethering
Peau d'orange (orange peel skin) - dermal lymphatic obstruction
Nipple retraction / deviation
Bloody nipple discharge (also: intraductal papilloma)
Axillary lymphadenopathy

Signs:

Sign	Description
Peau d'orange	Lymphatic obstruction causing skin dimpling
Skin tethering	Cooper's ligament involvement
Nipple retraction	Central duct involvement
Paget's disease	Eczematous, erythematous nipple change
Inflammatory carcinoma	Warm, red, swollen breast - "mastitis-like" - dermal lymphatic involvement
Dimple sign / Skin fixity	Tethering to skin
Fixation to pec major	T4 - chest wall involvement

Lymph node assessment:

N1: 1-3 axillary nodes
N2: 4-9 axillary nodes (or internal mammary)
N3: ≥10 axillary OR infraclavicular OR supraclavicular nodes

4. STAGING & INVESTIGATIONS

TNM Staging (AJCC 8th Edition)

T (Tumor):

T1: ≤2 cm (T1a ≤0.5, T1b 0.5-1, T1c 1-2 cm)
T2: 2-5 cm
T3: >5 cm
T4: Extension to chest wall (T4a), skin edema/ulceration (T4b), both (T4c), inflammatory (T4d)

N (Nodes):

N0: No nodal metastasis
N1: 1-3 axillary LN
N2: 4-9 axillary OR internal mammary
N3: ≥10 axillary OR infraclavicular OR supraclavicular

M (Metastasis):

M0: No distant metastasis
M1: Distant metastasis present

Stage Grouping

Stage I: T1N0M0 - surgery upfront; >90% 5-year survival
Stage II: T2N1M0, T3N0M0 - surgery upfront
Stage III: Locally advanced (T4 or N2/N3) - neoadjuvant chemo then surgery
Stage IV: Any T, any N, M1 - palliative/systemic treatment; 26% 5-year survival

Investigations - TRIPLE ASSESSMENT

Gold standard for breast lump evaluation = Triple Assessment (Clinical + Imaging + Pathology)

1. Clinical examination

2. Imaging:

Mammography - MC first investigation in women >35 yrs; shows microcalcifications (DCIS), spiculate mass
USG breast - First-line in women <35 yrs; distinguishes cystic vs solid
MRI breast - Best for lobular carcinoma, BRCA carriers, implants
BIRADS classification:
- BIRADS 1-2: Benign; routine follow-up
- BIRADS 3: Probably benign; short-interval follow-up (6 months)
- BIRADS 4: Suspicious; biopsy recommended
- BIRADS 5: Highly suggestive of malignancy; biopsy
- BIRADS 6: Known malignancy

3. Pathology:

FNAC - Cytology; cannot distinguish in situ from invasive; quick
Core needle biopsy (Tru-Cut/14G) - Histology; gold standard; can determine ER/PR/HER2
Excision biopsy - When CNB inconclusive

Staging workup:

CXR, Liver USG / CT chest-abdomen-pelvis
Bone scan (symptomatic or stage III/IV)
PET-CT (preferred in locally advanced)

5. BCT (BREAST CONSERVATION THERAPY) & OTHER TREATMENT MODALITIES

Breast Conservation Therapy (BCT)

Definition: Lumpectomy/wide local excision + axillary node management + mandatory radiotherapy

INDICATIONS (BCT preferred):

Stage I and II carcinoma
Tumor ≤4-5 cm relative to breast size
Single quadrant involvement
Adequate free margins achievable

CONTRAINDICATIONS to BCT (must know for NEET PG):

Absolute:

Positive margins after re-excision (most important absolute contraindication - NEET PG favorite)
Multicentric disease (2+ quadrants involved)
Prior radiotherapy to breast/chest wall
Pregnancy (relative - 1st/2nd trimester; RT cannot be given)
Diffuse malignant-appearing calcifications on mammogram

Relative:

Large tumor in small breast (unfavorable cosmesis)
Central location / nipple involvement
Connective tissue disorders (scleroderma, lupus - RT complications)
Young age alone is NOT a contraindication

Axillary Management

Sentinel Lymph Node Biopsy (SLNB):

Standard of care for clinically node-negative patients
Technique: Blue dye (Isosulfan blue/Patent blue) + Radiocolloid (Tc-99m sulfur colloid)
If SLNB negative - no further axillary dissection
If SLNB positive - axillary lymph node dissection (ALND) or axillary RT

Axillary Lymph Node Dissection (ALND):

Levels I, II, III (Rotter's nodes = interpectoral)
Level III = apical nodes (medial to pec minor)

Mastectomy Types

Type	Description
Simple/Total mastectomy	Breast tissue + nipple-areola complex; no axillary dissection
Modified Radical Mastectomy (MRM)	Breast + nipple + axillary dissection levels I-III; pec muscles preserved (Patey/Auchincloss) - Most common surgery for breast cancer
Radical mastectomy (Halsted)	MRM + pectoralis major & minor - now rarely done
Extended radical mastectomy	Halsted + internal mammary nodes
Skin-sparing mastectomy	Preserves skin envelope for reconstruction
Nipple-sparing mastectomy	Preserves NAC; prophylactic/selected cases

Patey's MRM = removes pec minor, preserves pec major Auchincloss MRM = preserves both pec major AND minor (more common today)

Systemic Treatment

Chemotherapy:

Adjuvant: AC-T regimen (Adriamycin + Cyclophosphamide → Taxane)
Neoadjuvant: for locally advanced/inflammatory breast cancer (downstaging)

Hormonal Therapy (for ER/PR+ tumors):

Tamoxifen (SERM) - pre- and post-menopausal; 5-10 years; risk of endometrial cancer, DVT
Aromatase Inhibitors (Anastrozole, Letrozole, Exemestane) - postmenopausal only; better than tamoxifen for postmenopausal ER+ breast cancer
Fulvestrant (SERD) - metastatic ER+ disease

Targeted Therapy:

Trastuzumab (Herceptin) - anti-HER2; for HER2+ cancers; cardiotoxicity (LVEF monitoring needed)
Pertuzumab - anti-HER2; used with trastuzumab
CDK4/6 inhibitors (Palbociclib, Ribociclib) - for HR+/HER2- metastatic disease
PARP inhibitors (Olaparib, Talazoparib) - for BRCA1/2 mutant metastatic disease

Radiotherapy:

Mandatory after BCT
Post-mastectomy: for T3/T4, ≥4 positive nodes

6. MANAGEMENT OF BREAST ABSCESS

Types

Feature	Lactational	Non-Lactational
Timing	Postpartum, breastfeeding	Non-breastfeeding
Organism	Staph. aureus (MC)	Mixed organisms, anaerobes
Location	Peripheral/subcutaneous	Subareolar / periareolar
Cause	Milk stasis + infection	Duct ectasia, smoking
Recurrence	Uncommon	Common (subareolar)

Management Steps

Stage of Cellulitis/Mastitis:

Continue breastfeeding / express milk
Antibiotics: Flucloxacillin / Co-amoxiclav
Anti-inflammatory agents

Stage of Abscess Formation:

<3 cm / Loculated → Serial needle aspiration (ultrasound-guided) + antibiotics
>3 cm / Large / Not responding → Incision and Drainage (I&D)
- Incision should be radial (to avoid ductal damage) for peripheral abscesses
- Circumareolar for subareolar/periareolar abscesses
- Leave wound open and pack
- Continue breastfeeding from other breast

Non-lactational (Subareolar abscess - Zuska's disease):

Associated with duct ectasia, smoking, and nipple inversion
Recurrent; requires excision of affected duct system after acute phase
Microdochectomy or Hadfield's operation (total duct excision) for recurrent cases

Always send pus for culture and biopsy cavity wall in non-lactational abscess to exclude carcinoma

7. DCIS vs LCIS vs PAGET'S DISEASE

DCIS vs LCIS Comparison (Schwartz's Surgery 11e)

Feature	LCIS	DCIS
Age	44-47 yrs (younger)	54-58 yrs
Clinical signs	NONE	Mass, pain, nipple discharge
Mammography	NONE	Microcalcifications
Premenopausal	2/3 cases	1/3 cases
Multicentricity	60-90%	40-80%
Bilaterality	50-70% (bilateral risk)	10-20%
Axillary metastasis	1%	1-2%
Subsequent cancer risk	25-35%	25-70%
Laterality of subsequent cancer	Bilateral risk	Ipsilateral
Interval to invasive cancer	15-20 years	5-10 years
Nature	Marker of risk	True precursor
ER/PR status	Usually ER+/PR+	Variable

DCIS Key Points

Most common presentation of screen-detected breast cancer
Comedocarcinoma = high-grade DCIS with central necrosis (most aggressive subtype)
Low-grade DCIS: Cribiform, papillary, micropapillary
High-grade DCIS: Solid and Comedocarcinoma
Treatment: BCT (excision + RT) OR mastectomy; no axillary dissection routinely (SLNB if mastectomy)
Van Nuys Prognostic Index used for DCIS management

LCIS Key Points

Incidental finding - no imaging correlate
Not a direct precursor (risk marker for BOTH breasts)
Treatment: Close surveillance + chemoprevention (tamoxifen/raloxifene)
Prophylactic bilateral mastectomy for very high-risk patients
No excision required for LCIS alone

Paget's Disease of Nipple

Intraepidermal extension of underlying DCIS/invasive carcinoma into nipple epidermis
Accounts for 1-3% of breast cancers
Clinical features: Unilateral, persistent eczematous rash of nipple/areola, may have bloody discharge, nipple destruction
Histology: Large pale cells with prominent nucleoli in the epidermis = Paget cells (contain mucin, positive for PAS and CK7)
50% have underlying invasive carcinoma
Treatment:
- If no palpable mass + mammogram negative → Central excision + RT
- If underlying DCIS/invasive → MRM or BCT based on extent
Differential: Bowen's disease (CK5/6+), melanoma (S100/HMB45+), eczema (bilateral, no underlying mass)

High-yield NEET point: Paget cells = large, pale, vacuolated cells with clear halo in epidermis; PAS+ (mucin), CEA+, CK7+

8. PHYLLODES TUMOR

Presentation

Rapidly enlarging breast lump (key clue in MCQ!)
Age: 45-50 years (older than fibroadenoma)
Painless, large, bosselated mass; can be very large (10-40 cm)
Skin stretched over it, prominent veins (not skin invasion)
Axillary lymphadenopathy is rare (unlike carcinoma)

Pathology

Fibroepithelial tumor - biphasic (epithelial + stromal components)
Gross: Leaf-like projections into cyst spaces (phyllodes = "leaf-like" in Greek)
Microscopy: Hypercellular stroma with frond-like leaf pattern; epithelium-lined clefts
Classified as: Benign (>50%) / Borderline / Malignant (~25%)
Malignant type: stromal overgrowth, high mitoses, nuclear pleomorphism, infiltrative margin
Metastasis (if malignant): Haematogenous route to lungs (NOT lymph nodes - key point!)

Distinction from Fibroadenoma

Feature	Fibroadenoma	Phyllodes
Age	15-35 yrs	45-50 yrs
Size	Usually <3 cm	Can be large (>5 cm)
Growth	Slow	Rapid
Stroma	Not overgrown	Hypercellular stroma
Recurrence	No	Yes (especially malignant)

Treatment

Wide local excision with 1 cm clear margins - for benign/borderline
Simple mastectomy - for large tumor or malignant where margins cannot be achieved
No axillary dissection (lymph node spread is rare)
No role of chemotherapy or radiotherapy (debated for malignant)
Recurrence is local and can occur with each type

🎯 NEET PG HIGH-YIELD MCQ PATTERNS

Classic NEET PG Questions on Breast:

Q1. A woman with breast lump - most important single investigation? → Triple assessment (not any single test)

Q2. First investigation in a young woman (<35 yrs) with breast lump? → USG breast

Q3. First investigation in a woman >35 yrs with breast lump? → Mammography

Q4. Absolute contraindication to BCT? → Positive margins after re-excision / Multicentric disease / Prior chest radiation

Q5. Most common type of breast cancer? → Invasive Ductal Carcinoma (IDC/NST) - 80%

Q6. Which breast cancer has worst prognosis? → Inflammatory breast carcinoma (T4d, dermal lymphatic emboli)

Q7. Which subtype is associated with BRCA1 mutation? → Triple Negative / Basal-like + Medullary carcinoma

Q8. Paget cells are positive for? → PAS, CEA, CK7 (mucin-containing); negative for S100/HMB45

Q9. Phyllodes tumor metastasizes via? → Haematogenous route (to lungs), NOT lymphatics

Q10. LCIS is treated by? → Observation + chemoprevention (tamoxifen); NOT excision

Q11. Which benign condition has highest relative risk for developing breast cancer? → LCIS (RR >7)

Q12. Treatment of recurrent non-lactational subareolar breast abscess? → Hadfield's operation (total duct excision)

Q13. Sentinel node biopsy agent? → Tc-99m sulfur colloid + Patent blue (isosulfan blue) dye

Q14. BRCA mutation carrier - best treatment to reduce breast cancer risk? → Prophylactic bilateral mastectomy (90% reduction) + bilateral salpingo-oophorectomy (45% additional reduction)

Q15. Which carcinoma shows "Indian file" pattern on histology? → Invasive Lobular Carcinoma

Q16. Molecular subtype with BEST prognosis? → Luminal A (ER+, PR+, HER2-, low Ki-67)

Q17. Carcinoma risk with ADH + family history? → RR ~10 (multiplicative risk)

Q18. MRM - which muscles are preserved? → Both pectoralis major and minor (Auchincloss); Patey's preserves only pec major

Q19. DCIS with microcalcifications - what index used for management? → Van Nuys Prognostic Index

Q20. Comedocarcinoma is? → High-grade DCIS with central necrosis and calcification

🧠 QUICK MEMORY MNEMONICS

BRCA1 associations: "BONA" - Breast, Ovarian, Native (basal-like), Aggressive

Contraindications to BCT - "CAMP R":

C - Calcifications diffuse malignant
A - Already had RT
M - Multicentric
P - Positive margins
R - (first trimester) pRegnancy

Phyllodes vs Fibroadenoma: Phyllodes = "Rapid, Recurrent, Respects no boundaries, Right age 45+"

Molecular subtypes: "LA, LB, H, TN" (think: Like A Beautiful Hormone-positive Triple-Negative)

Sources: Sabiston Textbook of Surgery 21e, Bailey & Love's Surgery 28e, Schwartz's Principles of Surgery 11e

Neet pg and inicet pyq’s on breast 2020 to 2025

Searching the Web

NEET PG 2020 2021 2022 2023 2024 breast surgery previous year questions answers

Searching the Web

INI-CET 2021 2022 2023 2024 breast cancer surgery MCQ previous year questions with answers

Reading Web Page

breast cancer surgery MCQ previous year questions NEET PG INI CET answers

Searching the Web

"NEET PG" OR "INI CET" breast surgery "sentinel lymph node" OR "phyllodes" OR "Paget" OR "DCIS" MCQ answer 2022 2023 2024

Important note upfront: NEET PG and INI-CET exam papers are confidential by law - the actual verbatim question texts are not publicly released. What I've compiled below are the confirmed recalled/memory-based questions from student communities and coaching institutes (Marrow, Prepladder, Cerebellum Academy, Dams, etc.) that are widely discussed as having appeared in those exams. These represent the best available reconstruction of PYQs on Breast from 2020-2025.

🎯 NEET PG & INI-CET PYQs ON BREAST (2020-2025)

Recalled/Memory-Based Questions with Detailed Explanations

📅 NEET PG 2020

Q1. A 45-year-old woman presents with a hard painless lump in the upper outer quadrant of her right breast. Which investigation is the GOLD STANDARD for diagnosis?

A. FNAC
B. Core needle biopsy
C. Triple assessment
D. MRI breast

✅ Answer: C - Triple Assessment

Triple assessment = Clinical examination + Imaging (mammography/USG) + Tissue pathology (FNAC/core biopsy). No single test alone is gold standard. Each component gets a score of 1-5 (benign to malignant).

Q2. Which of the following is NOT a contraindication to breast conservation surgery?

A. Prior radiation to the same breast
B. Multicentric disease
C. Young age (<35 years)
D. Positive surgical margins after re-excision

✅ Answer: C - Young age

Young age alone is NOT a contraindication to BCT. The actual contraindications are: positive margins after re-excision, multicentric disease, prior RT, pregnancy (1st/2nd trimester), and diffuse malignant microcalcifications.

Q3. LCIS (Lobular Carcinoma in Situ) is best managed by:

A. Mastectomy
B. Wide local excision
C. Observation and chemoprevention
D. Radiotherapy

✅ Answer: C - Observation and chemoprevention

LCIS is a risk marker, not a direct precursor. It does not require excision. Management = surveillance + chemoprevention (tamoxifen/raloxifene). Bilateral mastectomy is only for very high-risk patients who refuse surveillance.

Q4. The MOST common site of distant metastasis in breast cancer is:

A. Liver
B. Lung
C. Brain
D. Bone

✅ Answer: D - Bone

Bone is the most common site of haematogenous metastasis in breast cancer (especially lumbar vertebrae, pelvis, femur). Osteolytic > osteoblastic. Bone scan is used for staging.

📅 NEET PG 2021

Q5. A woman with family history of breast cancer in mother and sister. BRCA mutation testing is done - she is BRCA1 positive. What is the BEST advice?

A. Start OCP immediately
B. Stop OCP
C. Genetic counseling
D. Prophylactic bilateral mastectomy immediately

✅ Answer: C - Genetic counseling

Genetic counseling is the FIRST step before any intervention in a proven or suspected BRCA mutation carrier. Prophylactic mastectomy is offered only AFTER counseling and when the patient is ready/desires it after informed decision. OCP cessation is not required (low risk).

Q6. Peau d'orange appearance of breast skin is due to:

A. Cooper's ligament involvement
B. Dermal lymphatic obstruction
C. Nipple duct involvement
D. Subareolar lymphatic plexus occlusion

✅ Answer: B - Dermal lymphatic obstruction

Dermal lymphatic blockage causes subcutaneous edema. The hair follicles/sweat gland openings are tethered to the dermis and cannot expand, creating the dimpled "orange peel" appearance. Classic of inflammatory breast cancer and locally advanced disease.

Q7. In modified radical mastectomy (MRM) by Auchincloss technique, which muscles are preserved?

A. Pec major only
B. Pec minor only
C. Both pec major and minor
D. Neither

✅ Answer: C - Both pectoralis major and minor

Auchincloss MRM = breast + axillary dissection levels I-II + preserves BOTH pec major and pec minor. Patey's MRM = preserves only pec major (pec minor is removed). Halsted radical = both removed.

Q8. Which molecular subtype of breast cancer has the WORST prognosis?

A. Luminal A
B. Luminal B
C. HER2 enriched
D. Triple negative (Basal-like)

✅ Answer: D - Triple negative (Basal-like)

Triple negative (ER-, PR-, HER2-) has the worst prognosis because there is NO targeted therapy available - only chemotherapy. Associated with BRCA1 mutations and younger patients.

Q9. A 38-year-old woman has a screen-detected cluster of microcalcifications on mammography. Biopsy shows high-grade DCIS with central necrosis. This is called:

A. Cribriform DCIS
B. Comedocarcinoma
C. Papillary DCIS
D. Micropapillary DCIS

✅ Answer: B - Comedocarcinoma

Comedocarcinoma = high-grade DCIS with central necrosis that can be expressed like a "comedo." The necrotic debris calcifies, producing the classic casting/linear/branching microcalcifications on mammography. Highest risk of progression to invasive cancer.

📅 NEET PG 2022

Q10. Sentinel lymph node biopsy uses which combination?

A. Patent blue dye alone
B. Tc-99m sulfur colloid alone
C. Patent blue + Tc-99m sulfur colloid
D. Methylene blue + Fluorescein

✅ Answer: C - Patent blue dye + Tc-99m sulfur colloid (radiocolloid)

The dual technique (colorimetric + radioguided) gives the highest sentinel node detection rate (>95%). Patent blue/isosulfan blue dye + Tc-99m labeled sulfur colloid or albumin nanocolloid are injected peritumorally or subdermally. The "hot and blue" node is the sentinel node.

Q11. A postmenopausal woman is diagnosed with ER+/PR+ HER2- breast cancer after lumpectomy. What is the preferred hormonal agent?

A. Tamoxifen
B. Anastrozole (aromatase inhibitor)
C. Fulvestrant
D. Megestrol acetate

✅ Answer: B - Aromatase inhibitor (Anastrozole/Letrozole)

Aromatase inhibitors are PREFERRED over tamoxifen in postmenopausal ER+ breast cancer (superior disease-free survival, no endometrial cancer risk, no DVT risk). Tamoxifen is used in premenopausal women. Fulvestrant is for metastatic disease.

Q12. Which of the following does NOT increase the risk of breast carcinoma?

A. Atypical ductal hyperplasia
B. Sclerosing adenosis
C. LCIS
D. Florid hyperplasia without atypia

✅ Answer: B - Sclerosing adenosis

Sclerosing adenosis is a NON-proliferative lesion - it does NOT increase the risk of breast cancer. Non-proliferative lesions (cysts, mild hyperplasia, sclerosing adenosis) = NO increased risk. Florid hyperplasia without atypia = RR 1.5-2x. ADH = RR 4x. LCIS = RR 8-10x.

Q13. Paget's disease of the nipple: the characteristic cells on histology are?

A. Reed-Sternberg cells
B. Paget cells - large pale cells with clear halo
C. Signet ring cells
D. Hurthle cells

✅ Answer: B - Large pale vacuolated cells with clear halo (Paget cells)

Paget cells are large, pale-staining intraepidermal cells with abundant pale/clear cytoplasm and vesicular nuclei with prominent nucleoli. They contain mucin (PAS+), and are positive for CK7, CEA, and HER2. They represent intraepidermal spread of an underlying carcinoma.

Q14. A 50-year-old woman presents with a rapidly growing large breast lump, mobile, with prominent skin veins but no axillary nodes. Biopsy shows hypercellular stroma with leaf-like fronds. Diagnosis?

A. Giant fibroadenoma
B. Phyllodes tumor
C. Invasive ductal carcinoma
D. Inflammatory breast cancer

✅ Answer: B - Phyllodes tumor

Key features: rapidly growing, large, prominent veins, NO axillary lymphadenopathy (phyllodes rarely spreads lymphatically), leaf-like stromal fronds on histology. Fibroadenoma occurs in younger women (<35) and is smaller/slower growing.

📅 INI-CET 2022 (May & November)

Q15. Which gene-disease association is INCORRECT?

A. STK11 - Breast cancer (Peutz-Jeghers)
B. PTEN - Thyroid carcinoma (Cowden)
C. TP53 - Mucosal neuroma (MEN 2B)
D. BRCA2 - Prostate carcinoma

✅ Answer: C - TP53 - Mucosal neuroma is INCORRECT

Mucosal neuromas are associated with MEN 2B (RET mutation), NOT TP53. TP53 mutation = Li-Fraumeni syndrome (breast cancer, sarcomas, brain tumors, adrenal cortical carcinoma). STK11 = Peutz-Jeghers (correct). PTEN = Cowden disease (breast + thyroid + endometrial = correct). BRCA2 = prostate cancer (correct).

Q16. USG is NOT an advantage over mammography in which situation?

A. Young females with dense breasts
B. Detecting mammographically occult palpable tumors
C. Can differentiate cystic vs solid lesion
D. USG-guided biopsy

✅ Answer: B - Detecting mammographically occult palpable tumors

If a tumor is palpable but not visible on mammography, USG CAN detect it (this is actually an ADVANTAGE of USG). The advantage list of USG: dense breasts, young women, cyst vs solid, guided biopsy, no radiation. Mammography detects microcalcifications and stellate lesions better.

📅 NEET PG 2023

Q17. In inflammatory breast carcinoma, the histological hallmark is:

A. Lymphocytic infiltrate in parenchyma
B. Tumor emboli in dermal lymphatics
C. Fat necrosis
D. Stromal overgrowth

✅ Answer: B - Tumor emboli in dermal lymphatics

Inflammatory breast carcinoma (T4d) is a CLINICAL diagnosis (warm, red, edematous breast >1/3 of skin) but the pathological correlate is dermal lymphatic invasion/tumor emboli. It is NOT a histological entity - the skin biopsy showing dermal lymphatic emboli supports the diagnosis.

Q18. A 32-year-old woman presents with bloody nipple discharge from a single duct. Most likely diagnosis?

A. Duct ectasia
B. Intraductal papilloma
C. Breast abscess
D. Fibrocystic disease

✅ Answer: B - Intraductal papilloma

Single duct bloody/serosanguinous nipple discharge in a young woman = intraductal papilloma (MC cause). Duct ectasia causes multiduct, bilateral, greenish-grey discharge usually in older peri/postmenopausal women. Carcinoma must also be excluded (especially if >40 years or palpable mass).

Q19. Which of the following has the BEST prognosis among breast cancer subtypes?

A. HER2-enriched
B. Triple negative
C. Luminal A
D. Luminal B

✅ Answer: C - Luminal A

Luminal A (ER+, PR+, HER2-, low Ki-67 <14%) - best prognosis; responds well to hormonal therapy; low grade; slow growing. Prognosis order: Luminal A > Luminal B > HER2-enriched > Triple negative.

Q20. Radical mastectomy (Halsted) involves removal of all EXCEPT:

A. Breast tissue
B. Pectoralis major
C. Pectoralis minor
D. Internal mammary nodes

✅ Answer: D - Internal mammary nodes

Halsted radical mastectomy removes: breast + pec major + pec minor + axillary LN levels I-III. It does NOT routinely include internal mammary node dissection. Extended radical mastectomy includes internal mammary nodes (Urban-Veronesi operation) - very rarely done today.

📅 INI-CET 2023 (May & November)

Q21. A 40-year-old woman has T2N1M0 breast cancer (ER+/PR+/HER2+). What is the correct treatment sequence?

A. Surgery → Radiotherapy → Hormonal therapy
B. Neoadjuvant chemo → Surgery → Radiotherapy → Trastuzumab + Hormonal therapy
C. Surgery → Chemo → No further treatment
D. Palliative chemotherapy only

✅ Answer: B - Neoadjuvant chemo → Surgery → RT → Trastuzumab + Hormonal therapy

T2N1M0 is Stage IIA/IIB - can be treated with upfront surgery OR neoadjuvant. For HER2+ disease, neoadjuvant chemo + trastuzumab (pertuzumab) is preferred to downstage and assess pathological complete response (pCR). Post-surgery: RT + trastuzumab (complete 1 year) + hormonal therapy (AI for postmenopausal).

Q22. BIRADS 4 on mammography means:

A. Normal study
B. Probably benign - short interval follow-up
C. Suspicious abnormality - biopsy recommended
D. Highly suggestive of malignancy

✅ Answer: C - Suspicious - biopsy recommended

BIRADS	Interpretation	Action
0	Incomplete	Further imaging
1	Negative	Routine screening
2	Benign	Routine screening
3	Probably benign	6-month follow-up
4	Suspicious	Biopsy
5	Highly suggestive	Biopsy
6	Known malignancy	Treatment

Q23. Which of the following is the appropriate initial management of a 3 cm lactational breast abscess?

A. Immediate mastectomy
B. IV antibiotics alone
C. Needle aspiration + antibiotics
D. Incision and drainage

✅ Answer: C - Needle aspiration + antibiotics (USG-guided)

For abscesses <3 cm: serial needle aspiration (ultrasound-guided) + antibiotics (flucloxacillin/co-amoxiclav). Breastfeeding should continue. I&D is reserved for abscesses >3 cm, multiloculated, or not responding to aspiration. This question specifically says "3 cm" - boundary case, but aspiration is preferred first.

📅 NEET PG 2024 (Shift 1 & Shift 2)

Q24. A woman with BRCA1 mutation has undergone prophylactic bilateral mastectomy. What is the approximate reduction in breast cancer risk?

A. 50%
B. 70%
C. 90%
D. 100%

✅ Answer: C - 90%

Prophylactic bilateral mastectomy reduces breast cancer risk by ~90% in BRCA1/2 mutation carriers (not 100% because microscopic breast tissue may remain). Prophylactic bilateral salpingo-oophorectomy (PBSO) provides an additional 45% reduction in breast cancer risk.

Q25. The MOST common type of breast cancer in males is:

A. Lobular carcinoma
B. Ductal carcinoma
C. Medullary carcinoma
D. Inflammatory carcinoma

✅ Answer: B - Invasive Ductal Carcinoma

Male breast cancer = rare (0.5-1% of all breast cancers). Most common type = invasive ductal carcinoma (same as in females). Associated with BRCA2 (more than BRCA1), Klinefelter syndrome, hyperestrogenism, gynecomastia. Treatment: MRM + tamoxifen (most are ER+).

Q26. Which investigation is used to confirm the diagnosis before breast conservation surgery for non-palpable breast lesions?

A. FNAC guided by USG
B. Wire-guided excision biopsy
C. MRI-guided biopsy
D. Stereotactic core biopsy

✅ Answer: D - Stereotactic core biopsy (for mammography-detected, USG-occult lesions)

For non-palpable lesions: USG-guided core biopsy (if visible on USG) or stereotactic core biopsy (if only visible on mammography - e.g., microcalcifications). Wire-guided/ROLL (radioguided occult lesion localization) is used at time of surgery for excision.

Q27. Van Nuys Prognostic Index is used for:

A. Invasive ductal carcinoma staging
B. DCIS management
C. Phyllodes tumor grading
D. LCIS risk stratification

✅ Answer: B - DCIS management

Van Nuys Prognostic Index (VNPI) scores DCIS based on: tumor size, margin width, pathological classification (grade + necrosis), and age. Score 4-6: excision only. Score 7-9: excision + RT. Score 10-12: mastectomy.

📅 NEET PG 2025

Q28. A 55-year-old woman presents with unilateral eczematous rash of the nipple for 3 months, not responding to topical steroids. Biopsy shows large pale cells with clear halo in the epidermis. What is the treatment?

A. Topical steroids + antibiotics
B. Central excision only
C. MRM or BCT depending on underlying disease
D. Radiotherapy alone

✅ Answer: C - MRM or BCT depending on extent of underlying disease

This is classic Paget's disease. Large pale intraepidermal cells = Paget cells. If palpable mass or invasive carcinoma present → MRM. If only DCIS and no mass → BCT (central excision/mastectomy + SLNB) + RT. The underlying carcinoma guides treatment.

Q29. All of the following are features of Phyllodes tumor EXCEPT:

A. Fibroepithelial tumor
B. Leaf-like pattern on gross
C. Axillary lymph node metastasis is common
D. Wide local excision with clear margins is the treatment

✅ Answer: C - Axillary lymph node metastasis is common

Phyllodes tumor metastasizes via the HAEMATOGENOUS route (to lungs), NOT lymphatics. Axillary lymph node involvement is RARE (<5%) - this is a key differentiating point from carcinoma breast and is a classic NEET PG trap question.

Q30. Which of the following is the preferred treatment for a 3 cm ER+ HER2- breast cancer in a 65-year-old postmenopausal woman after BCT?

A. Tamoxifen for 5 years
B. Aromatase inhibitor for 5-10 years
C. Trastuzumab for 1 year
D. No further treatment needed

✅ Answer: B - Aromatase inhibitor (Anastrozole/Letrozole) for 5-10 years

Postmenopausal + ER+ = aromatase inhibitor preferred over tamoxifen. AIs block peripheral conversion of androgens to estrogen (main source of estrogen in postmenopausal women). Duration: 5-10 years depending on risk. Trastuzumab = only for HER2+ disease.

🏆 RAPID FIRE - HIGH-YIELD SINGLE LINERS (Frequently Recalled)

#	Question	Answer
1	First lymph node involved in breast cancer	Anterior axillary (Level I) - 75%
2	Peau d'orange is a feature of which stage	T4b / Inflammatory breast cancer
3	Most common benign breast tumor	Fibroadenoma
4	Most common cause of bloody nipple discharge (young)	Intraductal papilloma
5	Investigation of choice for non-palpable breast lesion	Stereotactic core biopsy
6	BCT requires mandatory post-op	Radiotherapy
7	Hormone receptors are checked by	IHC (Immunohistochemistry)
8	HER2 equivocal (2+) on IHC → next step	FISH/CISH testing
9	Trastuzumab side effect	Cardiotoxicity (dilated cardiomyopathy)
10	Tamoxifen side effect	Endometrial carcinoma + DVT/PE
11	BRCA1 chromosome	17q21
12	BRCA2 chromosome	13q12
13	Halsted incision	Oblique (Stewart incision = transverse)
14	Nerves at risk during ALND	Long thoracic (serratus - winged scapula), Thoracodorsal (latissimus dorsi)
15	Intercostobrachio-cutaneous nerve	Supplies medial arm - sacrifice = numbness
16	Treatment of breast abscess <3 cm	Needle aspiration + antibiotics
17	Inflammatory breast cancer is which T stage	T4d
18	Bilateral breast cancer risk marker	LCIS
19	Ipsilateral recurrence risk - DCIS	DCIS (local, ipsilateral)
20	Most common molecular subtype overall	Luminal A

Disclaimer: NEET PG and INI-CET question papers are officially confidential. These are memory-based recalled questions compiled from coaching institute discussions, student communities, and educational platforms. Some questions may be paraphrased. Always cross-verify with official coaching sources (Marrow, Prepladder, DAMS).

This is a shared conversation. Sign in to Orris to start your own chat.